Cassava's Alzheimer's Therapy: A Confidence Bet [Seeking Alpha]
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
The research behind Cassava Sciences' Alzheimer's drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and other associated researchers that have come under a great deal of scrutiny for what appears to be altered data. Now the SEC has fined the company $40 million, with individual fines for two of its former executives. The numbers appear to allegedly have been cooked at every level. It appears that an honest, competent look at the data would have shown that the drug did not work at all. But those Phase III trials are still ongoing, and the question is "why"? Dobrila Vignjevic/E+ via Getty Images Just about a year ago, I wrote here about Cassava Biosciences ( NASDAQ: SAVA ). It's a pretty tangled story, and I won't try to recapitulate it all in this post. But it's about their drug candidate This article was written by Derek Lowe 3.87K Follower s Follow Derek Lowe, an Arkansan by birt
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Cassava Sciences Appoints Freda Nassif as Chief Commercial OfficerGlobeNewswire
- Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- What Makes Cassava Sciences (SAVA) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Cassava Sciences, Inc. (NASDAQ: SAVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $116.00 price target on the stock.MarketBeat
SAVA
Earnings
- 11/7/24 - Beat
SAVA
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 3
- 11/20/24 - Form 4
- SAVA's page on the SEC website